Turoctocog alfa pegol (Esperoct®) – Hemophilia A

1. Characteristics

Start date 01.08.2019
Resolution 06.02.2020
INN Turoctocog alfa pegol
Brand name Esperoct®
Company Novo Nordisk Pharma GmbH
ATC code B02BD02
DDD 1 TU P
Therapeutic area Hematopoietic diseases CV
Reason for procedure New INN

SubgroupIndicationComparator
Patienten ab einem Alter von 12 Jahren mit Hämophilie A (angeborener Faktor-VIII-Mangel) Rekombinante oder aus humanem Plasma gewonnene Blutgerinnungsfaktor-VIII-Präparate

10. Associated procedures

Resolution INN Brand name Indication Additional benefit
Turoctocog alfa pegolEsperoct®Hemophilia A


<< List of all resolutions